Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Celcuity Inc CELC

Healthcare Biotechnology
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and... see more

Current News (NDAQ:CELC)

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

GlobeNewswire 3 days ago

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

GlobeNewswire December 11, 2025

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

GlobeNewswire November 26, 2025

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

GlobeNewswire November 26, 2025

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

GlobeNewswire November 17, 2025

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2025

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

GlobeNewswire November 5, 2025

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

GlobeNewswire November 4, 2025

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

GlobeNewswire October 18, 2025
View More News ››

Opinion & Analysis (NDAQ:CELC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CELC)

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway so good luck to all
coolfooldumbguy - July 28, 2025
View more Bullboard ››

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. engages in the acquisition and exploration of mineral properties in Chile and Argentina. The company ...
View More »

Podcasts